3 results
Primary Safety Objective * Proportion of patients who complete 24 weeks of combination treatment on pirfenidone at a dose of 1602*2403 mg/d and nintedanib at a dose of 200*300 mg/d Secondary Safety Objective * Proportion of patients who discontinue…
The aim of this study is to compare the effect of a postoperativenegative pressure dressing (Prevena (TM) IMS) with a standardwound dressing (care as usual) in clean closed surgical wounds on the prevention of wounddehiscence in low riks and high…
Primary Objective** To compare the PFS of melflufen plus dexamethasone (Arm A) versus pomalidomide plus dexamethasone (Arm B) as assessed by the Independent Review Committee (IRC) according to the International Myeloma Working Group Uniform Response…